Company Contents
Quick Facts & Snapshot
Summary
The global apheresis market is entering a scale-up phase as procedure volumes rise, donor safety standards tighten, and collection efficiency becomes critical. Leading Apheresis market companies are consolidating share through installed-base expansion and service contracts. With the market reaching US$ 3.68 Billion in 2025 and projected to hit US$ 6.32 Billion by 2032, the sector will grow at a robust 8.10% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The ranking of Apheresis market companies in this analysis is based on a multi-factor, weighted scoring framework. Core criteria include 2025 apheresis-related revenue, three-year growth trajectory, and global installed base of apheresis systems and disposables. Additional weight is assigned to technology differentiation, breadth of product portfolio across therapeutic and donor apheresis, and regulatory approvals. Service coverage, uptime guarantees, and the ability to execute long-term maintenance and managed-collection contracts are also evaluated. Qualitative input on project wins, KOL adoption, and depth of clinical evidence further refines scores. Each company receives normalized scores across criteria, which are then combined into a composite index to determine ranking positions, ensuring an objective, data-driven comparison across diverse Apheresis market companies.
Top 10 Companies in Apheresis
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Terumo BCT, Inc.
Terumo BCT is a global leader in blood component, therapeutic apheresis, and cell-therapy collection technologies serving hospitals and blood centers worldwide.
Haemonetics Corporation
Haemonetics delivers integrated blood management, plasma collection, and apheresis solutions with a strong emphasis on software-enabled operational efficiency.
Fresenius Kabi AG
Fresenius Kabi combines transfusion, cell therapy, and apheresis capabilities, supplying hospitals and collection centers with integrated solutions.
Asahi Kasei Medical Co., Ltd.
Asahi Kasei Medical focuses on membrane and adsorption-based therapeutic apheresis systems addressing autoimmune and renal indications.
B. Braun Melsungen AG
B. Braun provides a portfolio of extracorporeal therapies, integrating apheresis with critical care and renal solutions for hospitals.
Kawasumi Laboratories, Inc.
Kawasumi Laboratories manufactures high-quality disposable sets and components used across multiple branded apheresis systems.
Medica S.p.A.
Medica specializes in filters, cartridges, and custom circuits for apheresis and dialysis, serving OEMs and hospitals.
Nikkiso Co., Ltd.
Nikkiso leverages its dialysis and extracorporeal technology heritage to offer selective apheresis-oriented systems.
Macopharma SA
Macopharma supplies blood bags, apheresis disposables, and filtration products primarily to blood services and transfusion centers.
Mallinckrodt Pharmaceuticals (Therakos)
Mallinckrodt’s Therakos business focuses on photopheresis platforms for immune-mediated conditions and transplant complications.
SWOT Leaders
Terumo BCT, Inc.
SWOT Snapshot
Largest global installed base, broad product portfolio, and strong clinical support for multiple therapeutic areas.
High dependence on capital-intensive hardware and complex integration across legacy systems.
Rising global plasma demand and growth of cell therapies requiring sophisticated collection technologies.
Pricing pressure from competitors and potential reimbursement changes affecting procedure economics.
Haemonetics Corporation
SWOT Snapshot
Deep relationships with large plasma networks and advanced software to optimize donor and center efficiency.
Concentration in North American plasma collection and exposure to donor availability cycles.
International expansion into high-growth plasma markets and development of next-generation automated platforms.
Regulatory scrutiny on plasma collection and competition from integrated technology ecosystems.
Fresenius Kabi AG
SWOT Snapshot
Integrated offering across transfusion, infusion, and apheresis with strong hospital penetration.
Complex organizational structure and competition for investment with other business units.
Surging demand for cell and gene therapies needing specialized apheresis collection systems.
Emerging specialized players and potential budget constraints in public hospital systems.
Apheresis Market Regional Competitive Landscape
North America is the largest and most mature region for Apheresis market companies, underpinned by high plasma-collection volumes and advanced hospital infrastructure. Terumo BCT, Haemonetics, and Fresenius Kabi dominate key accounts through integrated device-disposable-service offerings, while Mallinckrodt’s Therakos systems secure a strong niche in photopheresis across major transplant centers.
In Europe, reimbursement-driven decision-making and strong public health systems favor proven clinical outcomes and cost-effectiveness. Apheresis market companies such as Fresenius Kabi, B. Braun, Macopharma, and Medica leverage long-standing hospital relationships and compliance with stringent EU regulatory standards, competing on safety, training quality, and long-term service contracts across therapeutic and donor apheresis segments.
Asia Pacific is the fastest-growing region, led by Japan, China, South Korea, and emerging ASEAN markets. Asahi Kasei Medical, Terumo BCT, and Nikkiso benefit from domestic bases in Japan, while global Apheresis market companies intensify localization efforts. Rising autoimmune disease diagnosis, investment in cell therapies, and expanding blood-collection networks drive robust equipment and disposables demand.
In the Middle East and Africa, market development is driven by government-backed healthcare modernization and the creation of national blood-transfusion networks. Apheresis market companies including B. Braun, Macopharma, and Terumo BCT increasingly win tenders by bundling training, maintenance, and technology transfer. Donor recruitment, workforce skills, and supply-chain resilience remain important differentiators among vendors.
Latin America presents a mixed landscape, combining advanced centers in Brazil, Mexico, and Argentina with underpenetrated secondary cities. Global Apheresis market companies focus on tiered offerings and financing solutions to address budget constraints. Haemonetics and Terumo BCT emphasize plasma and platelet collection systems, while regional distributors support after-sales service and regulatory navigation.
Central and Eastern Europe, including Poland, Romania, and the Baltics, are transitioning from aging equipment to modern, automated platforms. Apheresis market companies such as Fresenius Kabi, Macopharma, and Medica gain share through competitive tenders, EU-funded modernization programs, and local training centers, emphasizing safety, traceability, and compatibility with existing blood-bank IT infrastructure.
Apheresis Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Cloud-native software platform that integrates with leading apheresis devices to optimize scheduling, predict consumable usage, and benchmark center performance in real time.
Developing compact, AI-assisted therapeutic apheresis systems targeting community hospitals with simplified workflows and reduced nursing time requirements.
Designing cost-optimized donor apheresis platforms and disposables tailored for high-volume plasma centers in emerging markets with constrained budgets.
Focused on modular adsorption cartridges for autoimmune diseases, enabling personalized apheresis regimens and seamless integration with existing extracorporeal platforms.
Specializes in precision cell-collection add-ons for CAR-T and gene-therapy workflows, enhancing cell viability and yield on standard apheresis systems.
Apheresis Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Apheresis market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Apheresismarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.